Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.

Glucagon-like peptide 1 in health and disease

Andersen, Andreas, Lund, Asger, Knop, Filip K., Vilsbøll, Tina·2018·Nature Reviews Endocrinology

Abstract

In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates insulin release and suppresses glucagon secretion in response to the ingestion of nutrients. GLP1 also delays gastric emptying and increases satiety. In patients with type 2 diabetes mellitus (T2DM), supraphysiological doses of GLP1 normalize the endogenous insulin response during a hyperglycaemic clamp. Owing to the short plasma half-life of native GLP1, several GLP1 receptor agonists (GLP1RAs) with longer half-lives have been developed for the treatment of T2DM. These compounds vary in chemical structure, pharmacokinetics and size, which results in different clinical effects on hyperglycaemia and body weight loss; these variations might also explain the difference in cardiovascular effect observed in large-scale cardiovascular outcome trials, in which certain GLP1RAs were shown to have a positive effect on cardiovascular outcomes. Owing to their metabolic effects, GLP1RAs are also considered for the treatment of several other lifestyle-induced conditions, such as obesity, prediabetes and liver disease. This Review provides insights into the physiology of GLP1 and its involvement in the pathophysiology of T2DM and an overview of the currently available and emerging GLP1RAs. Furthermore, we review the results from the currently available large-scale cardiovascular outcome trials and the use of GLP1RAs for other indications.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41574-018-0016-2

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 116 references

Research works printed but not linked: 5

  1. Intarcia Therapeutics, Inc. Press release - intarcia announces FDA filing acceptance of new drug application (NDA) for ITCA 650 for the treatment of type 2 diabetes. Intarcia Therapeutics, Inc. http://www.intarcia.com/media/press-releases/2017-feb-3-intarcia-announces-fda-filing-acceptance.html (2017).
  2. Choi, I. et al. Superagonistic mechanism of increased glucodynamic and weight loss effects of LAPSCA-exendin-4 (efpeglenatide) [abstract]. Diabetologia 58 (Suppl. 1), 1–607 (2015).
  3. Yoon, K.-H. et al. Dose-response improvements in glycaemic control and body weight reduction with HM11260C, a once weekly GLP-1 receptor agonist with liraglutide as reference, in type 2 diabetes.[abstract]. Diabetologia 58, 1–607 (2015).
  4. Intarcia Therapeutics, Inc. Press release - Intarcia announces successful cardiovascular safety results in phase 3 FREEDOM-CVO Trial for ITCA 650, an investigational therapy for type 2 diabetes. Intarcia Therapeutics, Inc. https://www.intarcia.com/media/press-releases/2016-may-6-cardiovascular-safety.html (2016).
  5. Madsbad, S. et al. Early weight loss responders to liraglutide 3.0 mg achieved greater weight loss and regression to normoglycaemia, and reduced development of T2D at 3 years, versus early nonresponders in the SCALE obesity and prediabetes trial [abstract]. Obes. Facts 9, 1–376 (2016).

Cited by

See all 543

Metadata

Authors
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T.
Affiliations
University of Copenhagen (DK)
Corresponding author
Vilsbøll, Tina
Venue
Nature Reviews Endocrinology
Published
2018-05-04
Volume
14
Issue
7
Pages
390-403
ISSN
  • 1759-5029 (ISSN-L)
  • 1759-5037
OpenAlex
W2800926943
Cited by
543
References
116
Citations by year
2026: 49 · 2025: 91 · 2024: 92 · 2023: 66 · 2022: 63 · 2021: 63 · 2020: 62 · 2019: 39 · 2018: 18
FWCI
7.00
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Reviews Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
Funders
Steno Diabetes Center Copenhagen (SDCC 3.F CMP)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
glucagon-like peptide-1, type 2 diabetes, incretins, insulin secretion, glucagon suppression, gastric emptying, satiety, obesity, prediabetes, liver disease, cardiovascular outcomes, pharmacokinetics, weight loss
MeSH terms
Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Gastric Emptying, Humans, Hypoglycemic Agents, Insulin, Male, Reference Values, Biomarkers, Case-Control Studies, Treatment Outcome, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like peptide 1 in health and disease. https://app.cochat.ai/papers/10.1038/s41574-018-0016-2
The paper
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018). Glucagon-like peptide 1 in health and disease. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-018-0016-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.